- In patients with human immunodeficiency virus (HIV)-hepatitis B virus (HBV) co-infection, tenofovir disproxil fumarate (TDF)-containing regimens were effective at stimulating hepatitis B envelope antigen (HBeAg) loss, HBeAg conversion, HBV surface antigen (HBsAg) loss, and HBsAg conversion.
- Findings should be interpreted with caution because of significant heterogeneity across all study arms.
Why this matters
- Randomised controlled trials (RCTs) with large sample sizes are required for the investigation of potential predictors and biological markers associated with strategies for achieving HBV remission in patients with HIV-HBV coinfection.
- Meta-analysis included 11 studies (3 RCTs and 8 prospective cohort studies) after a search across electronic databases.
- Funding: The National 13th Five-Year Grand Program on Key Infectious Disease Control and others.
- TDF-based regimens were effective at stimulating:
- HBeAg loss (event rate [ER], 0.249; 95% CI, 0.155-0.376; I2, 55.78%) and conversion (ER, 0.237; 95% CI, 0.145-0.376; P<.001 for both and>
- HBsAg loss (ER, 0.073; 95% CI, 0.044-0.119) and conversion (ER, 0.055; 95% CI, 0.02-0.142; P<.001 for both>
- High level of heterogeneity.